High-dose bevacizumab therapy may lead to less need for retreatment for ROP
- Posted on: Jun 1 2023
- Leave a response
For retinopathy of prematurity (ROP), treating with high-dose bevacizumab vs low-dose bevacizumab or any dose of ranibizumab may mean a lower rate of retreatment.
Source: AAO
Posted in: Uncategorized